Health

Results: 145-156 of 5143

Following a planned interim analysis in the PROCEED trial Lundbeck expands the dose finding to intravenous administration of Lu AG09222 in migraine prevention

Sobi publishes Annual and sustainability report for 2024

Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

PR Newswire associated0

Human Frontier Science Program: Fellowships Awarded to 60 Pioneering Postdoctoral Scientists from 25 Nations

OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod

Isomorphic Labs announces $600 million funding to further develop its next-generation AI drug design engine and advance therapeutic programs into the clinic

ABEC Unveils Breakthrough Single Use Bioreactor Technology for Cell Therapy Manufacturing

David Ferrando, Ferrer's Chief Marketing and Market Access Officer and Jorge Cuneo, Ferrer's Chief Medical Officer, at the IMPAHCT opening session.

Experts Set International and Multidisciplinary Collaboration As Priorities in Pulmonary Hypertension Management

PR Newswire associated0

HAS Healthcare Advanced Synthesis SA acquires Cerbios-Pharma SA to create leading international Group in the CDMO sector, backed by 65 Equity Partners

ICON plc Schedules First Quarter 2025 Earnings Conference Call

In 2008, GN Corp initiated research with NCRM, Chennai, Tamil Nadu, India on restoring corneal blindness using buccal tissue epithelial cells. An out of the box idea of Dr. Suryaprakash, Urologist from Hyderabad, India in 2012 to apply buccal (oral) mucosal cells to repair stricture-inflicted male urethra, led to a clinical study, which he presented in NCRM NICHE 2017 in Tokyo, kickstarting a collaboration with Dr. Akio Horiguchi, National Defence Medical College, Japan, as they met in EAU in 2018 (Top right picture). Upon confirming successful cell engraftment in urethral stricture pre-clinical models taking help from the Dept. of Medical Engineering of NDMC between 2018~2023, (Bottom, right picture), now in 2025, clinical application has been initiated in Edogawa Hospital, Tokyo. Main picture: BEES-HAUS team after the first clinical transplant in Edogawa Hospital, Tokyo; Dr.Horiguchi (Centre) with Dr.Shojiro Katoh (President, Edogawa Hospital) standing left to him.

Cell therapy for male urethral stricture: BEES-HAUS clinical application in Edogawa Hospital Japan, reports Dr. Akio Horiguchi in IMORU.

BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer